Financials Aker BioMarine

Equities

AKBM

NO0010886625

Fishing & Farming

Market Closed - Oslo Bors 10:45:00 2024-04-26 EDT 5-day change 1st Jan Change
71.3 NOK -1.79% Intraday chart for Aker BioMarine +0.56% +55.00%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,291 4,756 3,335 4,033 6,251 - -
Enterprise Value (EV) 2 12,250 7,551 7,194 7,904 10,092 9,851 9,463
P/E ratio -172 x -61.7 x 35.3 x -41.1 x 23.6 x 29.7 x 16.1 x
Yield - - - - - - -
Capitalization / Revenue 4.25 x 2.04 x 1.18 x 1.13 x 1.54 x 1.37 x 1.24 x
EV / Revenue 5.06 x 3.25 x 2.55 x 2.21 x 2.49 x 2.16 x 1.88 x
EV / EBITDA 18.7 x 17.7 x 10.3 x 10.6 x 10.4 x 7.98 x 6.73 x
EV / FCF -22.5 x -11.1 x -27.2 x 497 x 115 x 36.8 x 25.3 x
FCF Yield -4.45% -8.98% -3.68% 0.2% 0.87% 2.72% 3.95%
Price to Book 3.23 x 1.45 x 0.9 x 1.08 x 1.55 x 1.48 x -
Nbr of stocks (in thousands) 87,586 87,586 87,638 87,673 87,673 - -
Reference price 3 13.78 6.166 3.883 4.525 6.456 6.456 6.456
Announcement Date 21-02-16 22-02-17 23-02-15 24-02-14 - - -
1USD in Million2NOK in Million3USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 2,420 2,327 2,817 3,572 4,055 4,552 5,031
EBITDA 1 - 654.9 426.4 701.1 745.8 972.4 1,235 1,406
EBIT 1 - 58.69 -120.5 224.6 56.47 417.7 592.6 474.5
Operating Margin - 2.43% -5.18% 7.97% 1.58% 10.3% 13.02% 9.43%
Earnings before Tax (EBT) 1 - 16.27 -69.81 124 -361.2 -171.7 253.8 110.4
Net income 1 -223.9 -35.3 -76.96 101.6 -95.89 -163.1 202.3 377.4
Net margin - -1.46% -3.31% 3.61% -2.68% -4.02% 4.45% 7.5%
EPS 2 -0.3400 -0.0800 -0.1000 0.1100 -0.1100 0.2734 0.2176 0.4000
Free Cash Flow 1 - -545.4 -677.8 -264.5 15.89 87.9 267.6 373.6
FCF margin - -22.54% -29.13% -9.39% 0.44% 2.17% 5.88% 7.43%
FCF Conversion (EBITDA) - - - - 2.13% 9.04% 21.68% 26.57%
FCF Conversion (Net income) - - - - - - 132.26% 98.99%
Dividend per Share 2 - - - - - - - -
Announcement Date 20-07-07 21-02-16 22-02-17 23-02-15 24-02-14 - - -
1NOK in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 516 672.4 532.6 746.5 705.7 802.7 725.7 886.3 1,058 883.3 860.3 1,059 1,037 960.1 915.9
EBITDA 1 122 63.97 75.82 217.6 195.4 210.3 - 215.1 278.4 188.6 167 242.8 320 275.9 154.5
EBIT 1 -18.47 -45.67 -51.48 155.6 66.52 60.97 - 62.02 117.4 -21.31 -61.53 88.28 154.5 110.4 -11.04
Operating Margin -3.58% -6.79% -9.67% 20.84% 9.43% 7.59% - 7% 11.1% -2.41% -7.15% 8.33% 14.89% 11.49% -1.2%
Earnings before Tax (EBT) 1 111.1 -78.99 -95.48 160.7 54.04 14.23 - -40.01 24.6 -160.9 -127.5 -22.07 55.18 11.04 -99.32
Net income 1 112.4 -80.88 -91.74 152.6 47.81 2.032 - -24.01 12.3 105.5 -130.8 -22.07 55.18 11.04 -99.32
Net margin 21.79% -12.03% -17.22% 20.44% 6.77% 0.25% - -2.71% 1.16% 11.94% -15.2% -2.08% 5.32% 1.15% -10.84%
EPS 0.1500 -0.1000 -0.1000 0.1700 0.0500 - -0.2000 -0.0300 0.0140 0.1060 - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 21-10-29 22-02-17 22-04-29 22-07-14 22-11-01 23-02-15 23-05-10 23-07-14 23-11-01 24-02-14 24-04-26 - - - -
1NOK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 1,958 2,795 3,859 3,871 3,841 3,600 3,212
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) - 2.99 x 6.555 x 5.504 x 5.19 x 3.95 x 2.916 x 2.285 x
Free Cash Flow 1 - -545 -678 -265 15.9 87.9 268 374
ROE (net income / shareholders' equity) - 6.54% -2.33% 2.67% -2.42% 6.47% 4.86% 2.5%
ROA (Net income/ Total Assets) - - -1.19% 1.27% -1.09% 0.44% 0.88% 1.2%
Assets 1 - - 6,461 8,027 8,789 -37,402 23,086 31,449
Book Value Per Share 2 - 4.260 4.270 4.320 4.180 4.160 4.380 -
Cash Flow per Share - - - - - - - -
Capex 1 - 265 701 422 486 269 269 275
Capex / Sales - 10.95% 30.13% 14.97% 13.61% 6.64% 5.92% 5.46%
Announcement Date 20-07-07 21-02-16 22-02-17 23-02-15 24-02-14 - - -
1NOK in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.456 USD
Average target price
5.778 USD
Spread / Average Target
-10.50%
Consensus
  1. Stock Market
  2. Equities
  3. AKBM Stock
  4. Financials Aker BioMarine